Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes [0.03%]
美国医疗保险受益人中2型糖尿病患者的社会决定因素与新降糖药的采纳情况
Wei-Han Chen,Yujia Li,Aokun Chen et al.
Wei-Han Chen et al.
Background: Two classes of newer glucose-lowering drugs (GLDs), sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, improve cardiovascular and renal outcomes among patients with type 2...
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data [0.03%]
基于输血状态和贫血严重程度评估医保住院患者医疗资源利用及成本：对医疗保险费用数据的回顾性分析
Aaron T Gerds,Joseph Tkacz,Laura Moore-Schiltz et al.
Aaron T Gerds et al.
Background: Myelofibrosis (MF) is a rare but aggressive myeloproliferative neoplasm that commonly affects older patients, with a mean age of onset of older than 60 years. At least a third of patients with primary MF are a...
Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basal insulin therapy [0.03%]
连续葡萄糖监测对二型糖尿病医保受益人因急诊就诊和全因住院率的影响：一项真实世界研究
Irl B Hirsch,Bhavya Sree Burugapalli,Laura Brandner et al.
Irl B Hirsch et al.
Background: The increasing prevalence of diabetes in the United States continues to drive a steady rise in health care resource utilization, especially emergency department visits and all-cause hospitalizations, and the a...
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure [0.03%]
连续葡萄糖监测测量和改进质量指标的使用：医疗保健有效性数据和信息集2024血糖管理指标的更新措施
Marissa Morris-Murray,Marie Frazzitta
Marissa Morris-Murray
Value-based diabetes care is a proactive approach to providing quality care to individuals with diabetes. This approach focuses on improving clinical outcomes rather than the volume of services provided. Implementation of value-based diabet...
Best practices and rationale for expanding Medicaid access to continuous glucose monitoring [0.03%]
扩大Medicaid对持续葡萄糖监测准入的最佳实践和原理
Cynthia A King,Amber N Lilly
Cynthia A King
Numerous studies have demonstrated that use of continuous glucose monitoring (CGM) significantly improves overall glycemic control and reduces the frequency and severity of hypoglycemic events in individuals treated with intensive insulin, ...
Halis Kaan Akturk,Anila Bindal
Halis Kaan Akturk
Ongoing innovations in glucose monitoring, insulin delivery, and telehealth technologies have created a digital diabetes ecosystem populated by connected tools and technologies that have been shown to improve clinical outcomes, lower costs,...
Innovation is the driver behind quality improvements in diabetes care delivery [0.03%]
创新是糖尿病治疗质量改进的动力
Irl B Hirsch,Christopher G Parkin
Irl B Hirsch
Evaluating the burden of illness of metabolic dysfunction-associated steatohepatitis in a large managed care population: The ETHEREAL Study [0.03%]
评估代谢功能障碍相关非酒精性肝炎在大型管理保健人群中的疾病负担：ETHEREAL研究
Michael Charlton,Ivy Tonnu-Mihara,Chia-Chen Teng et al.
Michael Charlton et al.
Background: Metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis) is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty ...
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder [0.03%]
利他普胺联合心理治疗对创伤后应激障碍的疗效和价值评估研究
Dmitriy Nikitin,Reem A Mustafa,Brett McQueen et al.
Dmitriy Nikitin et al.
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States [0.03%]
曲妥珠单抗及其生物仿制药和其他人表皮生长因子受体2抑制剂在美国的使用及患者特征
Xiaodan Mai,Aaron B Mendelsohn,James Marshall et al.
Xiaodan Mai et al.
Background: Trastuzumab is an antihuman epidermal growth factor receptor 2 monoclonal antibody used to treat breast and other cancers. Trastuzumab biosimilars were approved in the United States beginning in 2017. Utilizat...